Empagliflozin influences blood viscosity and wall shear stress in subjects with type 2 diabetes mellitus compared with incretin-based therapy

Cardiovascular Diabetology

Volumn 17, Issue 1, 2018, Pages

  Irace, Concetta ^a   Casciaro, Francesco ^a   Scavelli, Faustina Barbara ^a   Oliverio, Rosa ^a   Cutruzzolà, Antonio ^a   Cortese, Claudio ^b   Gnasso, Agostino ^a  

^a UNIVERSITY MAGNA GRAECIA OF CATANZARO   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Blood viscosity; Empagliflozin; Intima plus media thickness; Rheology; Shear stress

Indexed keywords

EMPAGLIFLOZIN; INCRETIN; INSULIN; LIRAGLUTIDE; METFORMIN; SITAGLIPTIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; BLOOD VISCOSITY; CALCULATION; CARDIOVASCULAR EFFECT; CAROTID ARTERY; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFECT; ECHOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OUTPATIENT; PROSPECTIVE STUDY; SHEAR STRESS; SOFTWARE; AGED; BLOOD; BLOOD FLOW; COMMON CAROTID ARTERY; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; MECHANICAL STRESS; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME;

AGED; BENZHYDRYL COMPOUNDS; BLOOD VISCOSITY; CAROTID ARTERY, COMMON; CAROTID INTIMA-MEDIA THICKNESS; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSIDES; HUMANS; INCRETINS; LIRAGLUTIDE; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; REGIONAL BLOOD FLOW; SITAGLIPTIN PHOSPHATE; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; STRESS, MECHANICAL; TIME FACTORS; TREATMENT OUTCOME;

EID: 85045194171     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/s12933-018-0695-y     Document Type: Article

References (43)

1. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Michaela Mattheus M, Devins T, Johansen OE, Woerle HJ, Broed UC, Inzucchi SE, for the EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-28.
2. Neal B, Perkovic V, Mahaffey KW, de Zeeuw D, Fulcher G, Erondu N, Shaw W, Law G, Desai M, Matthews DR. CANVAS Program Collaborative Group. N Engl J Med. 2017;377:644-57.
3. Zou H, Zhou B, Xu G. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease. Cardiovasc Diabetol. 2017. https://doi.org/10.1186/s12933-017-0547-1.
4. Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, Obokata N, Tsuda-Tsukimoto M, Saito A, Arakawa K, Ueta K, Shiotani M. Intestinal sodium glucose cotransporter 1 inhibition enhances glucagon like peptide 1 secretion in normal and diabetic rodents. J Pharmacol Exp Ther. 2015;354:279-89.
5. Inzucchi SE, Zinman B, Wanner C, Ferrari R, Fitchett D, Hantel S, Espadero RM, Woerle HJ, Broedl UC, Johansen OE. SGLT-2 inhibitors and cardiovascular risk: proposed pathways and review of ongoing outcome trials. Diabates Vasc Dis Res. 2015;12:90-100.
6. Lytvyn Y, Biornstad P, Udell JA, Lovshin JA, Cherney DZI. Sodium glucose cotransporter-2 inhibition in heart failure: potential mechanisms, clinical applications, and summary of clinical trials. Circulation. 2017;136:1643-58.
7. Habibi J, Aroor AR, Sowers JR, Jia G, Hayden MR, Garro M, Barron B, Mayoux E, Rector RS, Whaley A, DeMarco V. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes. Cardiovasc Diabetol. 2017. https://doi.org/10.1186/s12933-016-0489-z.
8. Chilton R, Tikkanen I, Cannon CP, Crowe S, Woerle HJ, Johansen OE. Effects of empagliflozin on blood pressure and markers of arterial stiffness and vascular resistance in patients with type 2 diabetes. Diabetes Obes Metab. 2015;17:1180-93.
9. Pfeifer M, Towensend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017. https://doi.org/10.1186/s12933-017-0511-0.
10. Sano M, Takei M, Shiraishi Y, Suzuki Y. Increased hematocrit during sodium-glucose cotransporter 2 inhibitor therapy indicates recovery of tubule-interstitial function in diabetic kidneys. J Clin Med Res. 2016;8:844-7.
11. Gnasso A, Carallo C, Irace C, Spagnuolo V, De Novara G, Mattioli PL, Pujia A. Association between intima-media thickness and wall shear stress in common carotid arteries in healthy male subjects. Circulation. 1996;94:3257-62.
12. Cooke JP, Rossitch E, Andon NA, LoScalzo J, Dzau VJ. Flow activates an endothelial potassium channel to release an endogenous nitrovasodilator. J Clin Invest. 1999;88:1663-71.
13. Irace C, Cortese C, Fiaschi E, Carallo C, Farinaro E, Gnasso A. Wall shear stress is associated with intima-media thickness and carotid atherosclerosis in subjects at low coronary heart disease. Stroke. 2004;35:464-8.
14. Standard Italiani per la cura del Diabete Mellito 2016. vol. 5, p. 91-117. http://www.standarditaliani.it. Accessed 20 June 2016.
15. Irace C, Carallo C, De Franceschi MS, Scicchitano F, Milano M, Tripolino C, Scavelli F, Gnasso A. Human common carotid wall shear stress as a function of age and gender: a 12-year follow-up study. Age. 2012;34:1553-62.
16. Imprialos KP, Boutari C, Stavropoulos K, Doumas M, Kara Giannis AI. Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality? J Neurol Neurosurg Psichiatry. 2017;88:249-53.
17. Kim Y, Babu AR. Clinical potential of sodium-glucose cotransporter 2 inhibitors in the management of type 2 diabetes. Diabetes Metab Syndr Obes. 2012;5:313-27.
18. Shah NK, Deeb WE, Choksi R, Epstein BJ. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2012;32:80-94.
19. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014;84:262-75.
20. Stavropoulos K, Imprialos KP, Bouloukou S, Boutari C, Doumas M. Hematocrit and Stroke: a forgotten and neglected link? Semin Thromb Hemost. 2017;43:591-8.
21. Tamariz LJ, Young JH, Pankow JS, Yeh HC, Schmidt MI, Astor B, Brancati FL. Blood viscosity and hematocrit as risk factors for type 2 diabetes mellitus: the atherosclerosis risk in communities (ARIC) study. Am J Epidemiol. 2008;168:1153-60.
22. Irace C, Carallo C, Scavelli F, De Franceschi MS, Esposito T, Gnasso A. Blood viscosity in subjects with normoglycemia and prediabetes. Diabetes Care. 2014;37:488-92.
23. Gnasso A, Cacia M, Cortese C, Succurro E, Andreozzi F, Carallo C, Irace C. No effect on the short-term of a decrease in blood viscosity on insulin resistance. Clin Hemorheol Microcirc. 2017. https://doi.org/10.3233/CH-170288.
24. Salazar Vázquez BY, Martini J, Chávez Negrete A, Tsai AG, Forconi S, Cabrales P, Johnson PC, Intaglietta M. Cardiovascular benefits in moderate increases of blood and plasma viscosity surpass those associated with lowering viscosity: experimental and clinical evidence. Clin Hemorheol Microcirc. 2010;44:75-85.
25. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32:650-7.
26. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, Ways K, Schwartz S. Canaglifloz in improves glycemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14:539-45.
27. Inzucchi SE, Zinman B, Fitchett D, Wanner C, Ferrannini E, Schumacher M, Schmoor C, Ohneberq K, Johansen OE, George JT, Hantel S, Bluhmki E, Lachin JM. How does empagliflozin reduce cardiovascular mortality? Insight from a mediation analysis of the EMPA-REG OUTCOME trial. Diabetes Care. 2018;41:356-63.
28. Schou M, Gullestad L, Fitchett D, Zinman B, Inzucchi SE, Hehnke U, von Eynatten M, George J, Johansen OE, Wanner C. Empagliflozin exerts short- and long-term effects on plasma volume in patients with type 2 diabetes: insight from EMPA-REG OUTCOME. Circulation. 2017;136:A15997.
29. Carallo C, Tripolino C, De Franceschi MS, Irace C, Xu XY, Gnasso A. Carotid endothelial shear stress reduction with aging is associated with plaque development in 12 years. Atherosclerosis. 2016;251:63-9.
30. Gnasso A, Irace C, Carallo C, De Franceschi MS, Motti C, Mattioli PL, Pujia A. In vivo association between low wall shear stress and plaque in subjects with asymmetrical carotid atherosclerosis. Stroke. 1997;28:993-8.
31. Irace C, Gnasso A, Cirillo F, Leonardo G, Ciamei M, Crivaro A, Renzulli A, Cotrufo M. Arterial remodeling of the common carotid artery after aortic valve replacement in patients with aortic stenosis. Stroke. 2002;33:2446-50.
32. O'Leary DH, Polak JF, Kronmal RA, Manolio TA, Burke GL, Wolfson SK. Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. N Engl J Med. 1999;340:14-22.
33. Braamskamp MJAM, Langslet G, McCrindle BW, Cassiman D, Francis GA, Gagne C, Gaudet D, Morrison KM, Wiegman A, Turner T, Miller E, Kusters DM, Raichlen JS, Martin PD, Stein EA, Kastelein JJP, Hutten BA. Effect of rosuvastatin on carotid intima-media thickness in children with heterozygous familial hypercholesterolemia: the CHARON study, hypercholesterolemia in children and adolescents taking rosuvastatin open label. Circulation. 2017;136:359-66.
34. Sala-Vila A, Romero-Mamani ES, Gilabert R, Núñez I, de la Torre R, Corella D, Ruiz-Gutiérrez V, López-Sabater MC, Pintó X, Rekondo J, Martínez-González MÁ, Estruch R, Ros E. Changes in ultrasound-assessed carotid intima-media thickness and plaque with a Mediterranean diet: a sub-study of the PREDIMED trial. Arterioscler Thromb Vasc Biol. 2014;34:439-45.
35. Geng DF, Jin DM, Wu W, Fang C, Wang JF. Effect of alpha-glucosidase inhibitors on the progression of carotid intima-media thickness: a meta-analysis of randomized controlled trials. Atherosclerosis. 2011;218:214-9.
36. Lorenz MW, Price JF, Robertson C, Bots ML, Polak JF, Poppert H, Kavousi M, Dörr M, Stensland E, Ducimetiere P, Ronkainen K, Kiechl S, Sitzer M, Rundek T, Lind L, Liu J, Bergström G, Grigore L, Bokemark L, Friera A, Yanez D, Bickel H, Ikram MA, Völzke H, Johnsen SH, Empana JP, Tuomainen TP, Willeit P, Steinmetz H, Desvarieux M, Xie W, Schmidt C, Norata GD, Suarez C, Sander D, Hofman A, Schminke U, Mathiesen E, Plichart M, Kauhanen J, Willeit J, Sacco RL, McLachlan S, Zhao D, Fagerberg B, Catapano AL, Gabriel R, Franco OH, Bülbül A, Scheckenbach F, Pflug A, Gao L, Thompson SG. Carotid intima-media thickness progression and risk of vascular events in people with diabetes: results from the PROG-IMT collaboration. Diabetes Care. 2015;38:1921-9.
37. Espeland MA, O'leary DH, Terry JG, Morgan T, Evans G, Mudra H. Carotid intima-media thickness as a surrogate for cardiovascular disease events in trials of HMG-CoA reductase inhibitors. Curr Control Trials Cardiovasc Med. 2005;6:3.
38. Byrkjeland R, Stensaeth KH, Anderssen S, Njerve IU, Arnesen H, Seljeflot SS. Effects of exercise training on carotid intima-media thickness in patients with type 2 diabetes and coronary artery disease. Influence of carotid plaques. Cardiovasc Diabetol. 2016. https://doi.org/10.1186/s12933-016-0336-2.
39. Katakami N, Mita T, Yoshii H, Shiraiwa T, Yasuda T, Okada Y, Umayahara Y, Kaneto H, Osonoi T, Yamamoto T, Kuribayashi N, Maeda K, Yokoyama H, Kosugi K, Ohtoshi K, Hayashi I, Sumitani S, Tsugawa M, Ohashi M, Taki H, Nakamura T, Kawashima S, Sato Y, Watada H, Shimomura I, UTOPIA study investigators. Rationale, design, and baseline characteristics of the Utopia Trial for preventing diabetic atherosclerosis using an SGLT2 inhibitor: a prospective, randomized, open-label, parallel-group comparative study. Diabetes Ther. 2017. https://doi.org/10.1007/s13300-017-0292-1.
40. Tanaka A, Murohara T, Taguchi I, Eguchi K, Suzuki M, Kitakaze M, Sato Y, Ishizu T, Higashi Y, Yamada H, Nanasato M, Shimabukuro M, Teragawa H, Ueda S, Kodera S, Matsuhisa M, Kadokami T, Kario K, Nishio Y, Inoue T, Maemura K, Oyama J, Ohishi M, Sata M, Tomiyama H, Node K. PROTECT Study Investigators Rationale and design of a multicenter randomized controlled study to evaluate the preventive effect of ipragliflozin on carotid atherosclerosis: the PROTECT study. Cardiovasc Diabetol. 2016. https://doi.org/10.1186/s12933-016-0449-7.
41. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, Josse R, Kaufman KD, Koglin J, Korn S, Lachin JM, McGuire DK, Pencina MJ, Standl E, Stein PP, Suryawanshi S, Van de Werf F, Peterson ED, Holman RR. TECOS study group. N Engl J Med. 2015;373:232-42.
42. Mita T, Katakami N, Shiraiwa T, Yoshii H, Onuma T, Kuribayashi N, Osonoi T, Kaneto H, Kosugi K, Umayahara Y, Yamamoto T, Matsumoto K, Yokoyama H, Tsugawa M, Gosho M, Shimomura I, Watada H, on behalf of the Collaborators on the Sitagliptin Preventive Study of Intima-Media Thickness Evaluation (SPIKE) Trial. Sitagliptin attenuates the progression of carotid intima-media thickening in insulin-treated patients with type 2 diabetes: the sitagliptin preventive study of intima-media thickness evaluation (SPIKE) a randomized controlled trial. Diabetes Care. 2016;39:455-64.
43. Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JFE, Nauck MA, Nissen SE, Pocock S, Poulter NR, Ravn LS, Steinberg WM, Stockner M, Bernard Zinman B, Bergenstal RM, Buse JB, for the LEADER Steering Committee on behalf of the LEADER Trial Investigators. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375:311-22.